Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.

Leukemia - 1 Sept 2024

Orvain Corentin, Bertoli Sarah, Peterlin Pierre, Desbrosses Yohann, Dumas Pierre-Yves, Iat Alexandre, Hospital Marie-Anne, Carre Martin, Tavernier Emmanuelle, Riou Jérémie, Bouvier Anne, Bidet Audrey, Tondeur Sylvie, Renosi Florian, Mozziconacci Marie-Joelle, Flandrin-Gresta Pascale, Dadone-Montaudié Bérengère, Delabesse Eric, Pigneux Arnaud, Hunault-Berger Mathilde, Recher Christian

Abstract excerpt

Patients with Core-Binding Factor (CBF) and NPM1-mutated acute myeloid leukemia (AML) can be monitored by quantitative PCR after having achieved first complete remission (CR) to detect morphologic relapse and drive preemptive therapy. How to best manage these patients is unknown. We retrospectively analyzed 303 patients with CBF and NPM1-mutated AML, aged 18-60 years, without allogeneic hematopoietic cell...

Topics

Join the communities discussing this publication.

Antineoplastic Combined Chemotherapy Protocols
Core Binding Factors
Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Neoplasm Recurrence, Local

Remission Induction

Salvage Therapy

Source

Open in PubMed Open full text

Identifiers

PMID: 39020060
DOI: 10.1038/s41375-024-02335-2
PMCID: PMC11347360

Genes

NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.PMID 39020060Read ↗

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.Semantic proximity Read ↗

The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse.Semantic proximity Read ↗

Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.Semantic proximity Read ↗

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO studySemantic proximity Read ↗

KIT and FLT3-ITD Mutations Do Not Predict Outcomes in Pediatric Core-Binding Factor Acute Myeloid Leukemia: Findings from the C-HUANAN-AML-15 Multicenter Cohort StudySemantic proximity Read ↗

KIT and FLT3-ITD mutations do not predict outcomes in pediatric core-binding factor acute myeloid leukemia: findings from the C-HUANAN-AML-15 multicenter cohort study.Semantic proximity Read ↗

Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.Semantic proximity Read ↗

Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.Semantic proximity Read ↗

Sequencing Identifies Relapse-Prone AML Patients.Semantic proximity Read ↗

Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.Semantic proximity Read ↗

ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.